Triple-Drug attack targets Hard-to-Treat leukemias
NCT ID NCT06401603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) in 30 adults with advanced chronic myeloid leukemia or a related acute leukemia. The goal is to find safe doses and see if the combo can control the disease in people who have not responded to or could not tolerate standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.